Trial Profile
Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS) in a Representative Iranian Population
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 02 Mar 2021
Price :
$35
*
At a glance
- Drugs Edaravone (Primary) ; Riluzole
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- 25 Mar 2019 Planned End Date changed from 16 Mar 2019 to 16 Sep 2019.
- 25 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 15 Jan 2018 Status changed from not yet recruiting to recruiting.